Amicus Therapeutics Balanced Scorecard
Fully Editable
Tailor To Your Needs In Excel Or Sheets
Professional Design
Trusted, Industry-Standard Templates
Pre-Built
For Quick And Efficient Use
No Expertise Is Needed
Easy To Follow
Unlock the Full Balanced Scorecard for Deeper Strategic Insight
This Amicus Therapeutics Balanced Scorecard Analysis gives you a clear, company-specific view of performance across financial, customer, internal process, and learning and growth areas. The page already shows a real preview of the analysis, so you can review the actual content before buying. Purchase the full version to get the complete ready-to-use report.
Benefits
Launch Clarity
Launch Clarity shows whether Galafold and Pombiliti/Opfolda are converting approvals into prescriptions, refill persistence, and payer wins. In rare disease, a small set of specialist accounts can drive most of the 2025 commercial signal, so launch tracking needs account-level data, not broad averages. For Amicus Therapeutics, that means watching 2025 new-starts, net revenue retention, and access coverage by key centers.
Access Tracking
Access tracking matters for Amicus Therapeutics because growth depends on diagnosis, reimbursement, and patient support, not just science. In 2025, the company still had two approved rare-disease therapies, so delays in enrollment or coverage can slow revenue fast. A scorecard should track time-to-treatment, hub enrollment, and coverage expansion so access gaps show up early.
R&D Gates
R&D gates matter at Amicus Therapeutics because the CompanyName ties its heavy 2025 development spend to clear milestones like trial enrollment, data readouts, and FDA filings. That matters when future growth still depends on the pipeline, not just on current sales from Galafold. It also makes burn control sharper, so management can stop weak programs sooner and fund the assets most likely to win approval.
Supply Reliability
For Amicus Therapeutics, supply reliability matters because specialty biologic chains can fail fast; monitoring batch release, on-time delivery, and deviation rates helps keep patients on therapy and revenue intact. In fiscal 2025, that means fewer stockouts and fewer costly quality holds across products like Pombiliti and Opfolda. A tight release process also lowers recall and expediting risk, which protects margins.
Global Expansion
Amicus Therapeutics sells in the U.S., Europe, Japan, and other markets, so a balanced scorecard can track which launches are gaining traction and which still need regulatory or sales support. In 2025, that view helps management shift capital toward the highest-return countries instead of spreading spend evenly. It also ties market access, pricing, and local execution to revenue growth, so weaker regions show up fast.
Amicus Gains: Faster Access, Stronger Coverage, Steadier Cash Flow
Benefits for Amicus Therapeutics in a 2025 balanced scorecard are clearer revenue conversion, faster access wins, and tighter use of R&D spend. With two rare-disease drugs on market, the upside is higher prescription depth, better payer coverage, and more predictable cash flow from specialist centers.
| 2025 Benefit Metric | Why It Matters |
|---|---|
| New-starts | Shows launch uptake |
| Coverage rate | Shows payer access |
| Time-to-treatment | Shows patient speed |
| Batch release | Shows supply reliability |
What is included in the product
Detailed Word Document
Editable Excel File
Drawbacks
Small Samples
Amicus Therapeutics relies on rare-disease pools, so even a few prescriptions or one payer decision can move the scorecard fast. In Fabry and Pompe, the addressable base is small versus primary-care drugs, so a change of just dozens of patients can alter revenue trends and access metrics. That makes 2025 balanced scorecard results more volatile and less stable than for large-scale franchises.
Benchmark Gaps
Benchmark gaps are real for Amicus Therapeutics because its 2 rare-disease franchises, Fabry and Pompe, do not map cleanly to big-pharma scorecards. A KPI like patient starts or persistence can look strong in a niche launch, but the same metric means something different in a broader biotech with many products. So peer comps can distort 2025 performance unless you compare only like-for-like rare-disease launches and franchise-specific metrics.
Cash Blind Spot
Cash Blind Spot: Amicus Therapeutics can score well on growth and internal process goals while cash burn still stays elevated. In fiscal 2025, the key test was not just revenue growth, but whether operating cash flow and free cash flow kept pace with launch spending and R&D. That matters because liquidity pressure can force equity raises and dilute holders even when the scorecard looks strong.
Binary Risks
Binary risks matter for Amicus Therapeutics because one Phase 3 miss or FDA delay can outweigh many smaller scorecard gains. The company still posted 2024 revenue of $500.5 million, but a single failed endpoint can quickly reset that base and the stock. So a balanced scorecard can make the risk look smoother than it really is.
- One miss can erase years of spend
- Approval delays hit value fast
Access Fragmentation
Amicus Therapeutics faces access fragmentation because reimbursement rules vary across the U.S. Medicaid is split across 50 state programs, while Europe spans 27 EU markets with different HTA and payer demands. A single scorecard can hide weak pull-through in one country even when global revenue looks steady.
This matters for rare-disease drugs: a launch can clear one payer but stall in another, delaying patient starts and cash collection. For Amicus, that means country-by-country issues can stay masked until they hit 2025 sales momentum.
Amicus 2025: Small Scale, Big Volatility
Amicus Therapeutics is still a small rare-disease name, so 2025 scorecard results can swing on a few patient starts, one payer win, or one delay. That makes growth and access metrics less stable than in larger biopharma franchises.
Cash use is another weak spot: the company can show launch progress while R&D and commercial spend still pressure free cash flow in 2025. Binary trial and FDA risks also mean one setback can wipe out several scorecard wins.
| Drawback | Why it hurts 2025 scorecard |
|---|---|
| Small patient base | High volatility from few scripts |
| Cash burn | Growth can outpace cash |
| Binary R&D risk | One miss can reset value |
What You See Is What You Get
Amicus Therapeutics Reference Sources
This is the actual Amicus Therapeutics Balanced Scorecard analysis document you'll receive after purchase – no sample, no placeholders. The preview below is pulled directly from the full report, so you're seeing the same professional content included in your download. Once you complete checkout, the full detailed version becomes available immediately.
Frequently Asked Questions
It measures whether Amicus is converting rare-disease science into repeatable commercial results. The most useful signals are 2 marketed product lines, 4 scorecard perspectives, and metrics such as net product sales, prescription starts, R&D milestones, and coverage wins. That gives investors a cleaner read than revenue alone.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site - including articles or product references - constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.